Dutch Biotech Merus Raises €21.7 Million
Merus, a Dutch developer of human therapeutic antibodies, has raised €21.7 million in Series B funding. Investors included The Novartis Option Fund, Pfizer, Bay City Capital, Life Sciences Partners and seed backer Aglaia Oncology Fund.
29 January 2010•5 mins read
